Distribution of Risk Factors Amongst Ocular Hypertension and Open-Angle Glaucoma Patients in Canada

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.1 site in 1 country410 target enrollmentNovember 2007

ConditionsGlaucoma, Open-Angle Ocular Hypertension

Overview

Phase: Not Applicable
Intervention: Not specified
Conditions: Glaucoma, Open-Angle
Sponsor: Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Enrollment: 410
Locations: 1
Primary Endpoint: To describe the presence and distribution of risk factors in subjects diagnosed with OH or OAG stratified according to geographic distribution in a Canadian population in the ophthalmologist practice.
Status: Completed
Last Updated: 5 years ago

Overview Investigators Eligibility Criteria Outcomes Sites Similar Trials

Overview

Brief Summary

This descriptive, non-interventional study will collect information on the presence of risk factors in newly diagnosed ocular hypertension and open-angle glaucoma patients in Canada.

Registry

clinicaltrials.gov

Start Date

November 2007

End Date

April 2009

Last Updated

5 years ago

Study Type

Observational

Sex

All

Investigators

Sponsor

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

Responsible Party

Sponsor

Eligibility Criteria

Inclusion Criteria

•Subjects diagnosed at study visit or within 3 months of visit with OH
•OAG (to include POAG, NTG, pigmentary and pseudoexfoliation glaucoma)

Exclusion Criteria

•No prior treatment for OH or OAG
•No prior ocular surgery or history of ocular trauma

Outcomes

Primary Outcomes

To describe the presence and distribution of risk factors in subjects diagnosed with OH or OAG stratified according to geographic distribution in a Canadian population in the ophthalmologist practice.

Time Frame: duration of study

Secondary Outcomes

To describe the severity of disease at the time of diagnosis and to determine if there is a correlation between risk factors, or number of risk factors, and the severity of disease at presentation.(duration of study)